| 000 | 01565 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250517162318.0 | ||
| 264 | 0 | _c20180514 | |
| 008 | 201805s 0 0 eng d | ||
| 022 | _a1873-4758 | ||
| 024 | 7 |
_a10.1016/j.drugpo.2017.05.027 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPuzhko, Svetlana | |
| 245 | 0 | 0 |
_aHigh hepatitis C incidence in relation to prescription opioid injection and poly-drug use: Assessing barriers to hepatitis C prevention. _h[electronic resource] |
| 260 |
_bThe International journal on drug policy _c09 2017 |
||
| 300 |
_a61-68 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnalgesics, Opioid _xadverse effects |
| 650 | 0 | 4 |
_aBehavior, Addictive _xepidemiology |
| 650 | 0 | 4 |
_aCanada _xepidemiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHepatitis C _xepidemiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aOpioid-Related Disorders _xepidemiology |
| 650 | 0 | 4 | _aPolypharmacy |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSeroconversion |
| 650 | 0 | 4 |
_aSubstance Abuse, Intravenous _xepidemiology |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aRoy, Élise | |
| 700 | 1 | _aJutras-Aswad, Didier | |
| 700 | 1 | _aArtenie, Andreea Adelina | |
| 700 | 1 | _aFortier, Emmanuel | |
| 700 | 1 | _aZang, Geng | |
| 700 | 1 | _aBruneau, Julie | |
| 773 | 0 |
_tThe International journal on drug policy _gvol. 47 _gp. 61-68 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.drugpo.2017.05.027 _zAvailable from publisher's website |
| 999 |
_c27328066 _d27328066 |
||